Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orchard To Work On Reversing English Funding Refusal For Libmeldy Gene Therapy

Reimbursement Discussions Are Also Ongoing In Other Major European Markets

Executive Summary

Health technology assessment body NICE has welcomed further discussion between Orchard Therapeutics and the National Health Service to resolve its concerns over the company’s one-time gene therapy for the neurodegenerative disorder, metachromatic leukodystrophy, in children.

You may also be interested in...



Libmeldy: ‘Significant Discount’ For World’s Most Expensive Drug Secures English Funding

Orchard Therapeutics has agreed to lower the price of its £2.8m gene therapy for children with metachromatic leukodystrophy following negotiations with the National Health Service. Meanwhile, reimbursement efforts in the rest of Europe are also gaining speed and a US filing is planned.

Libmeldy Gene Therapy Brings Considerable Extra Benefit, Says German Body

With talks to form a new coalition progressing in Germany, the new government, which could take office in early December, is expected to introduce measures to curb pharmaceutical spending. Orphan drugs could be among products targeted.

‘Substantial’ Discount Helps Zolgensma Win Access In UK

The English and Scottish health technology appraisal bodies NICE and the Scottish Medicines Consortium have given the green light to Novartis/Avexis’ costly gene therapy, Zolgensma.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel